Search by tag Трейдинг


Pool Corp. (POOL) Gains But Lags Market: What You Should Know

Pool Corp. (POOL) closed the most recent trading day at $356.94, moving +1.11% from the previous trading session. This change lagged the S&P 500's 3.06% gain on the day. Meanwhile, the Dow gained 2.68%, and the Nasdaq, a tech-heavy index, lost 0.09%. Heading into today, shares of the distributor of supplies for swimming pools had lost 11.93% over the past month, lagging the Consumer Discretionary sector's loss of 6.59% and the S&P 500's loss of 4.31% in that time. Investors will be hoping for strength from Pool Corp. as it approaches its next earnings release. On that day, Pool Corp. is projected to report earnings of $7.40 per share, which would represent year-over-year growth of 16.17%. Meanwhile, our latest consensus estimate is calling for revenue of $2.12 billion, up 18.76% from the prior-year quarter. Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $18.50 per share and revenue of $6.33 billion. These totals would mark changes of +21.87% and +19.49%, respectively, from last year. Investors should also note any recent changes to analyst estimates for Pool Corp.These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Pool Corp. is holding a Zacks Rank of #3 (Hold) right now. Investors should also note Pool Corp.'s current valuation metrics, including its Forward P/E ratio of 19.09. For comparison, its industry has an average Forward P/E of 7.57, which means Pool Corp. is trading at a premium to the group. We can also see that POOL currently has a PEG ratio of 1.91. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Leisure and Recreation Products stocks are, on average, holding a PEG ratio of 0.95 based on yesterday's closing prices. The Leisure and Recreation Products industry is part of the Consumer Discretionary sector. This group has a Zacks Industry Rank of 70, putting it in the top 28% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow POOL in the coming trading sessions, be sure to utilize Zacks.com. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Click to get this free report Pool Corporation (POOL): Free Stock Analysis Report To r…

Crown Castle (CCI) Gains But Lags Market: What You Should Know

Crown Castle (CCI) closed at $174.99 in the latest trading session, marking a +1.99% move from the prior day. The stock lagged the S&P 500's daily gain of 3.06%. Meanwhile, the Dow gained 2.68%, and the Nasdaq, a tech-heavy index, lost 0.09%. Heading into today, shares of the operator of wireless communications towers had lost 8.51% over the past month, lagging the Finance sector's loss of 6.6% and the S&P 500's loss of 4.31% in that time. Crown Castle will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $1.79, up 4.68% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $1.71 billion, up 8.2% from the prior-year quarter. CCI's full-year Zacks Consensus Estimates are calling for earnings of $7.38 per share and revenue of $6.94 billion. These results would represent year-over-year changes of +6.19% and +9.53%, respectively. Investors should also note any recent changes to analyst estimates for Crown Castle. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.05% higher. Crown Castle is holding a Zacks Rank of #3 (Hold) right now. In terms of valuation, Crown Castle is currently trading at a Forward P/E ratio of 23.25. For comparison, its industry has an average Forward P/E of 12.57, which means Crown Castle is trading at a premium to the group. The REIT and Equity Trust - Other industry is part of the Finance sector. This group has a Zacks Industry Rank of 102, putting it in the top 41% of all 250+ industries. The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow CCI in the coming trading sessions, be sure to utilize Zacks.com. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Click to get this free report Crown Castle International Corporation (CCI): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions…

Centene (CNC) Stock Sinks As Market Gains: What You Should Know

Centene (CNC) closed the most recent trading day at $82.95, moving -0.82% from the previous trading session. This change lagged the S&P 500's daily gain of 3.06%. Meanwhile, the Dow gained 2.68%, and the Nasdaq, a tech-heavy index, lost 0.09%. Prior to today's trading, shares of the healthcare company had gained 2.14% over the past month. This has outpaced the Medical sector's loss of 2.37% and the S&P 500's loss of 4.31% in that time. Centene will be looking to display strength as it nears its next earnings release. In that report, analysts expect Centene to post earnings of $1.69 per share. This would mark year-over-year growth of 35.2%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $35.44 billion, up 14.23% from the year-ago period. CNC's full-year Zacks Consensus Estimates are calling for earnings of $5.62 per share and revenue of $142.41 billion. These results would represent year-over-year changes of +9.13% and +13.04%, respectively. Investors should also note any recent changes to analyst estimates for Centene. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 2.56% higher. Centene currently has a Zacks Rank of #3 (Hold). In terms of valuation, Centene is currently trading at a Forward P/E ratio of 14.89. This valuation marks a discount compared to its industry's average Forward P/E of 16.01. Also, we should mention that CNC has a PEG ratio of 1.05. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - HMOs stocks are, on average, holding a PEG ratio of 1.18 based on yesterday's closing prices. The Medical - HMOs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 86, which puts it in the top 34% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Click to get this free report Centene Corporation (CNC): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions ex…

Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $30.44, moving -1.17% from the previous trading session. This change lagged the S&P 500's 3.06% gain on the day. Meanwhile, the Dow gained 2.68%, and the Nasdaq, a tech-heavy index, lost 0.09%. Heading into today, shares of the company had gained 20.78% over the past month, outpacing the Medical sector's loss of 2.37% and the S&P 500's loss of 4.31% in that time. Investors will be hoping for strength from Cassava Sciences, Inc. as it approaches its next earnings release. On that day, Cassava Sciences, Inc. is projected to report earnings of -$0.42 per share, which would represent a year-over-year decline of 223.08%. It is also important to note the recent changes to analyst estimates for Cassava Sciences, Inc.These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Cassava Sciences, Inc. is holding a Zacks Rank of #3 (Hold) right now. The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 146, putting it in the bottom 43% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Click to get this free report Cassava Sciences, Inc. (SAVA): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opin...

Clorox (CLX) Gains But Lags Market: What You Should Know

Clorox (CLX) closed at $140.75 in the latest trading session, marking a +0.46% move from the prior day. This move lagged the S&P 500's daily gain of 3.06%. Elsewhere, the Dow gained 2.68%, while the tech-heavy Nasdaq lost 0.09%. Heading into today, shares of the consumer products maker had lost 4.3% over the past month, lagging the Consumer Staples sector's loss of 1.3% and outpacing the S&P 500's loss of 4.31% in that time. Investors will be hoping for strength from Clorox as it approaches its next earnings release. The company is expected to report EPS of $0.98, up 3.16% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $1.87 billion, up 3.83% from the year-ago period. For the full year, our Zacks Consensus Estimates are projecting earnings of $4.16 per share and revenue of $7.18 billion, which would represent changes of -42.62% and -2.23%, respectively, from the prior year. Investors might also notice recent changes to analyst estimates for Clorox. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Clorox is currently sporting a Zacks Rank of #3 (Hold). Digging into valuation, Clorox currently has a Forward P/E ratio of 33.68. This valuation marks a premium compared to its industry's average Forward P/E of 24.36. We can also see that CLX currently has a PEG ratio of 4.81. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. CLX's industry had an average PEG ratio of 4.03 as of yesterday's close. The Soap and Cleaning Materials industry is part of the Consumer Staples sector. This group has a Zacks Industry Rank of 196, putting it in the bottom 23% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Click to get this free report The Clorox Company (CLX): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opi…

Illumina (ILMN) Gains But Lags Market: What You Should Know

In the latest trading session, Illumina (ILMN) closed at $193.93, marking a +0.2% move from the previous day. This change lagged the S&P 500's 3.06% gain on the day. Elsewhere, the Dow gained 2.68%, while the tech-heavy Nasdaq lost 0.09%. Prior to today's trading, shares of the genetic testing tools company had lost 20.54% over the past month. This has lagged the Medical sector's loss of 2.37% and the S&P 500's loss of 4.31% in that time. Illumina will be looking to display strength as it nears its next earnings release. In that report, analysts expect Illumina to post earnings of $0.63 per share. This would mark a year-over-year decline of 66.31%. Meanwhile, our latest consensus estimate is calling for revenue of $1.22 billion, up 8.27% from the prior-year quarter. For the full year, our Zacks Consensus Estimates are projecting earnings of $4.10 per share and revenue of $5.2 billion, which would represent changes of -30.51% and +14.92%, respectively, from the prior year. Any recent changes to analyst estimates for Illumina should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Illumina is currently sporting a Zacks Rank of #3 (Hold). Digging into valuation, Illumina currently has a Forward P/E ratio of 47.26. Its industry sports an average Forward P/E of 21.22, so we one might conclude that Illumina is trading at a premium comparatively. We can also see that ILMN currently has a PEG ratio of 1.52. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. ILMN's industry had an average PEG ratio of 1.11 as of yesterday's close. The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 103, which puts it in the top 41% of all 250+ industries. The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Zacks.com. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Click to get this free report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions ex…

Black Stone Minerals (BSM) Gains But Lags Market: What You Should Know

Black Stone Minerals (BSM) closed at $13.48 in the latest trading session, marking a +1.81% move from the prior day. The stock lagged the S&P 500's daily gain of 3.06%. At the same time, the Dow added 2.68%, and the tech-heavy Nasdaq lost 0.09%. Prior to today's trading, shares of the partnership that owns mineral and royalty interests had lost 16.41% over the past month. This has lagged the Oils-Energy sector's loss of 12.66% and the S&P 500's loss of 4.31% in that time. Wall Street will be looking for positivity from Black Stone Minerals as it approaches its next earnings report date. The company is expected to report EPS of $0.40, up 60% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $159.37 million, up 172.71% from the year-ago period. BSM's full-year Zacks Consensus Estimates are calling for earnings of $1.68 per share and revenue of $587.34 million. These results would represent year-over-year changes of +80.65% and +63.49%, respectively. It is also important to note the recent changes to analyst estimates for Black Stone Minerals. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 9.05% higher. Black Stone Minerals is currently a Zacks Rank #1 (Strong Buy). Valuation is also important, so investors should note that Black Stone Minerals has a Forward P/E ratio of 7.9 right now. For comparison, its industry has an average Forward P/E of 10.51, which means Black Stone Minerals is trading at a discount to the group. The Energy and Pipeline - Master Limited Partnerships industry is part of the Oils-Energy sector. This group has a Zacks Industry Rank of 4, putting it in the top 2% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow BSM in the coming trading sessions, be sure to utilize Zacks.com. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >> Click to get this free report Black Stone Minerals, L.P. (BSM): Free Stock Analysis Report To read this article on Zacks.com…

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue